Opioid Study Designed to Improve Addiction Treatment Outcomes
Written by Craig Rogers, in Section Empowered Recovery
Patient recruitment is underway for a genomics-based pilot program to study opioid abuse and addiction, a first step in extending precision medicine into clinical practice for addictions, says CRO Genemarkers.
The study is designed to determine if PGX testing can improve treatment response to opioids for chronic pain and medication-assisted treatment for opioid addiction. It also aims to identify genetic markers of addiction – which could support initial opioid prescribing and potentially prevent addiction in the future, Langerveld said.
CRO supporting genomics-based opioid study designed to improve addiction treatment
Published on Outsourcing Pharma.com on April 9th, 2018 and written By Melissa Fassbender
Patient recruitment is underway for a genomics-based pilot program to study opioid abuse and addiction – a first step in extending precision medicine into clinical practice for addiction, says CRO Genemarkers.
Devastating consequences of the opioid epidemic include increases in opioid misuse and related overdoses, as well as the rising incidence of newborns experiencing withdrawal syndrome due to opioid use and misuse during pregnancy.
Drug overdose deaths continue to increase in the United States.
- From 1999 to 2016, more than 630,000 people have died from a drug overdose.
- Around 66% of the more than 63,600 drug overdose deaths in 2016 involved an opioid.
- In 2016, the number of overdose deaths involving opioids (including prescription opioids and illegal opioids like heroin and illicitly
- manufactured fentanyl) was 5 times higher than in 1999.
- On average, 115 Americans die every day from an opioid overdose.1
1. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2017. Available at http://wonder.cdc.gov.